VentriPoint Diagnostics LtdOTCQB:VPTDFView on Canadian Exchange
- LAST PRICE0.1016
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0697/ 100
- Ask / Lots0.1250/ 50
- Open / Previous Close--- / 0.1016
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VPTDF |
|---|---|---|
| 11:18 ET | 800 | 0.1012 |
| 11:21 ET | 100 | 0.1025 |
| 11:30 ET | 100 | 0.09765 |
| 11:32 ET | 100 | 0.09765 |
| 11:41 ET | 100 | 0.099 |
| 11:43 ET | 600 | 0.1043 |
| 11:45 ET | 300 | 0.099 |
| 11:50 ET | 200 | 0.1043 |
| 11:54 ET | 100 | 0.1045 |
| 01:58 ET | 100 | 0.09585 |
| 02:43 ET | 100 | 0.1007 |
| 03:57 ET | 300 | 0.0994 |
| 04:00 ET | 100 | 0.1016 |
Nov 19, 2024
Ventripoint Announces New Sales Program to Accelerate Growth in U.S. Market for AI-Powered Echocardiography Solutions, from 8:16AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:16AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 14, 2024
Nov 6, 2024
Ventripoint Announces Amended Non-Brokered Convertible Debenture Private Placement and Shares for Debt Transaction, from 8:17AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:17AM ET on Wednesday Nov 06, 2024 by Dow Jones
Oct 24, 2024
Ventripoint Receives EU CE Mark for Next Generation, AI-powered Heart-scanning Technology, from 8:16AM ET on Thursday Oct 24, 2024 by Dow Jones
8:16AM ET on Thursday Oct 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
VentriPoint Diagnostics Ltd | 21.0M | --- | --- |
Company Information
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.
Contact Information
- Headquarters
- 18 Hook Ave, Unit 101TORONTO, ON, Canada M6P 1T4
- Phone
- 416-848-4156
- Fax
- 416-848-0709
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.0M |
|---|---|
Revenue (TTM) | $72.1K |
Shares Outstanding | 161.4M |
VentriPoint Diagnostics Ltd does not pay a dividend. | |
Beta | 0.69 |
EPS | $-0.03 |
Book Value | $0.00 |
P/E Ratio | --- |
Price/Sales (TTM) | 291.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,915.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
